恶性黑色素瘤是最具侵袭性和致死性的皮肤癌，全球发病率不断上升。在过去的5年中，美国食品和药物管理局已经批准了6种靶向治疗或免疫治疗转移性黑色素瘤(Chapman et al.， 2011;Falchook et al.， 2012;Hauschild et al.， 2012;Hodi等，2010;Ribas et al.， 2015;Topalian et al.， 2014)。干预措施第一次提高了这种致命疾病的生存率。然而，抗ctla -4或抗pd -1单克隆抗体对BRAF/MEK抑制剂的快速耐药和较低的客观反应率或免疫相关副作用限制了其广泛的临床应用。
期刊介绍：
Journal of Investigative Dermatology Symposium Proceedings (JIDSP) publishes peer-reviewed, invited papers relevant to all aspects of cutaneous biology and skin disease. Papers in the JIDSP are often initially presented at a scientific meeting. Potential topics include biochemistry, biophysics, carcinogenesis, cellular growth and regulation, clinical research, development, epidemiology and other population-based research, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, pharmacology and percutaneous absorption, photobiology, physiology, and skin structure.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
